Medical Management of Well-Differentiated Pancreatic Neuroendocrine Tumors: From Conventional Therapies to Emerging Strategies.

J Clin Med · 2026 · PMC12986171 · PMID 41827131

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

In long-term follow-up, median OS was 38.6 months with sunitinib and 29.1 months with placebo; however, this difference did not reach statistical significance, likely because 69% of placebo-treated patients crossed over to receive sunitinib [ 51 ].

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.